Penumbra Inc (N:PEN)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: One Penumbra Place
ALAMEDA CA 94502
Tel: N/A
Website: https://www.penumbrainc.com
IR: See website
<
Key People
Adam Elsesser
Chairman of the Board, President, Chief Executive Officer
Maggie S. Yuen
Chief Financial Officer
Johanna Roberts
Executive Vice President, General Counsel, Secretary
Lambert Shiu
Chief Accounting Officer
   
Business Overview
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Financial Overview
For the nine months ended 30 September 2024, Penumbra Inc revenues increased 14% to $879.1M. Net loss totaled $19.7M vs. income of $36.7M. Revenues reflect Vascular segment increase of 27% to $595.3M, United States segment increase of 18% to $654.2M, International segment increase of 2% to $224.9M. Net loss reflects Sales, General and Administrative -Other increase of 16% to $395.3M (expense).
Employees: 4,200 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $9,024M as of Sep 30, 2024
Annual revenue (TTM): $1,164M as of Sep 30, 2024
EBITDA (TTM): $143.16M as of Sep 30, 2024
Net annual income (TTM): $34.55M as of Sep 30, 2024
Free cash flow (TTM): $134.18M as of Sep 30, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 38,379,199 as of Oct 16, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.